Rectal Cancer
New rectal cancer study findings have been published by W. Rhomberg and colleagues
Published in Drug Week, October 19th, 2007
According to recent research published in the journal Strahlentherapie und Onkologie, "In an earlier phase II study, irradiation together with razoxane was shown to improve Local control in recurrent rectal cancer. Therefore, the Austrian Society of Radiooncology (oGRO) initiated a randomized controlled trial in 1992 to compare this combined treatment versus radiation therapy alone. Between 1992 and 1999, 36 patients with localized recurrences of rectal cancer were randomized to receive radiotherapy without (group A) or with razoxane (group B)."
"The prognostic variables of the two groups were similar except for a longer median latency period from initial surgery...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
Source: Drug Week (2007-10-19)
More Articles from Drug Week
- Addiction Medicine
Scripps research study reveals mechanism behind nicotine dependency - Angiogenesis
Combination therapy reverses effects of portal hypertension in rats - Biomedicine
FDA approves knee-injury device for humans - Breast Cancer
Manchester researchers announce new methods of beating breast cancer - Cancer
MU researchers studying model to learn why certain cancers become resistant to drugs - Cancer
New strategies with greater anti tumorous efficacy - More from this issue of Drug Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
